FDA setback for Sanofi’s Tolebrutinib in progressive MS
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
Subscribe To Our Newsletter & Stay Updated